微芯生物(688321.SH)：西奥罗尼胶囊获药物临床试验批准

Core Viewpoint - Microchip Biotech (688321.SH) has received approval from the National Medical Products Administration for clinical trials of its product, Xioroni Capsules, in combination with Tislelizumab and chemotherapy for first-line treatment of metastatic pancreatic ductal adenocarcinoma [1] Group 1 - The company has been granted a Clinical Trial Approval Notice for its product [1] - The clinical research will focus on the treatment of metastatic pancreatic ductal adenocarcinoma [1] - The study will involve a combination therapy approach, utilizing both Xioroni Capsules and Tislelizumab alongside chemotherapy [1]